PebbleAtlas
PEBBLE / ATLAS
Open research access
PRECLINICAL PUBLICATION · 2017

The Toll-Like Receptor 2/6 Agonist, FSL-1 Lipopeptide, Therapeutically Mitigates Acute Radiation Syndrome.

Mouse / Radiation

Evidence by therapy association

Study details and outcomes are extracted in the context of a specific intervention. Separate associations are retained rather than silently merged.

PMID 29230065 ↗2017Reported benefit

The Toll-Like Receptor 2/6 Agonist, FSL-1 Lipopeptide, Therapeutically Mitigates Acute Radiation Syndrome.

MouseRadiationC57BL/6 wild type and Myd88-deficientMale and femalen = Approximately 8 to 10 mice per arm across 8 independent sur…Intraperitoneal injection, total volume 50 to 70 microlitres per mouse0.25 mg/kg24 hours after total body irradiation, with a separate arm dosed at 48 hours

Model: Total body gamma irradiation at 8.8 Gy or 9.2 Gy from a caesium source

A single 0.25 mg/kg dose of FSL-1 at 24 hours after 9.2 Gy gave mean 30-day survival of 80.3 per cent across 8 independent experiments versus 22.4 per cent in untreated males, was superior to CpG, flagellin and MPLA (p = 0.0005), was effective in females (88.89 versus 14.29 per cent, p = 0.002), re…

Extraction: extract · Supplied extraction confidence: 0.95. Machine-extracted fields require source verification.